The Pulmonary Hypertension Association (PHA) provides this tool to help participants learn more about research ongoing in PH. Use the filters below to narrow the search results to fit your personal needs. Each listing describes current research, who qualifies to participate, and whom to contact for information.
No personal information can be collected through this tool. The information presented on the PHA Clinical Trials page has been obtained directly from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH). PHA recommends that you use the information in this resource to begin a conversation with your PH specialist about whether or not participating in research is right for you.
Due to radiation exposure and low but real risk of morbidity and mortality associated with
right heart catheterization, non-invasive procedures to estimate mPAP are desired for the
diagnosis of PH or to monitor treatment effectiveness. Echocardiography is used as a
screening tool to estimate systolic pulmonary arterial pressure (sPAP), but due various
limitations, this technique is not considered to be sufficiently accurate for the diagnosis
of PH. The aim of 4D flow MRI is to evaluate the complete time-varying tridirectional
velocity field in a volume of interest. It enables flow and velocity measurements in a
vascular region of...
mTOR activation has been shown to be relevant in the development and progression of pulmonary
hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension
in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in
This is a prospective, longitudinal, observational study of free-living activity trackers and
patient reported outcomes to test the hypothesis that daily activity will have stronger
prognostic value than 6MWD in patients with pulmonary hypertension after 12 weeks.
This study is a prospective, non-randomized, two arm, single-center acute feasibility study
assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH
The main objective of this study is to analyze the survival of a cohort of patients admitted
for acute decompensation of pulmonary arterial hypertension or postembolic pulmonary
hypertension and to establish the prognostic value of biomarkers.
This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose
TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial
hypertension.The trial is expected to include 60 patients, divided into 6 groups, according
to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil
tablets 20mg, 40mg group, each group 10 cases.
This prospective, observational, multicenter, patient registry will follow patients who are
receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram
In this prospective study, the investigators will implement a systematic assessment of
adherence to diuretics in a cohort of patients with precapillary pulmonary hypertension.
This study is designed to:
- determine the overall adherence rates for diuretic regimen
- determine the determinants of non-adherence to diuretics
- assess the risk of PH worsening occurrence in the non-adhesion group
This is a first-in-human (FIH), single-blind, placebo-controlled, single-centre study
designed to assess the safety and tolerability of PDNO in healthy male and female subjects.
In addition, the exposure of 1,2 propanediol (PD) will be evaluated.
The study will be conducted in 2 parts:
Part I: single ascending dose (SAD), 7 cohorts, 30 minutes intravenous (iv) infusion of
placebo followed by 1 hour iv infusion of PDNO to assess safety, tolerability and PD exposure
in healthy male and female subjects.
Part II: ascending doses of PDNO in 2 cohorts, 30 minutes iv infusion of placebo followed by
3 ascending doses of PDNO in...
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored
trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these
trials until lack of patient benefit as assessed by investigator, or commercial availability